Use of Antiparkinsonian Drugs among Patients with Parkinson's Disease in the United Kingdom

被引：0
|
作者：
Schade, Rene [1 ]
Dieleman, Jeanne [1 ]
Sturkenboom, Miriam [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
253
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [1] Trends in the prescription of antiparkinsonian drugs among patients with Parkinson's disease in the United Kingdom: A population-based analysis
    Schade, R.
    Dieleman, J. P.
    Sturkenboom, M. C.
    [J]. MOVEMENT DISORDERS, 2011, 26 : S286 - S286
  • [2] Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease
    Taguchi, Soutarou
    Koide, Hirofumi
    Oiwa, Hiroko
    Hayashi, Miku
    Ogawa, Kazuhiro
    Ito, Chihiro
    Nakashima, Koji
    Yuasa, Tomoko
    Yasumoto, Akihiro
    Ando, Hiroaki
    Fujikake, Akifumi
    Fukuoka, Takaaki
    Tokui, Keisuke
    Izumi, Masayuki
    Tsunoda, Yuka
    Kawagashira, Yuichi
    Okada, Yohei
    Niwa, Jun-ichi
    Doyu, Manabu
    [J]. PLOS ONE, 2021, 16 (07):
  • [3] Impaired sensory gating in Parkinson's disease patients is corrected with antiparkinsonian drugs
    Fricke, D.
    Ghisolfi, E. S.
    Becker, J.
    Schuch, A.
    Ramos, F. L.
    Lara, D. R.
    Chaves, M. L.
    Rieder, C. R.
    [J]. MOVEMENT DISORDERS, 2006, 21 : S365 - S365
  • [4] Prevalence of mental health disorders among patients with Parkinson's disease in the United Kingdom
    Potluri, Rahul
    Natalwala, Ammar
    Nakajima, Mitsuko
    Lavu, Deepthi
    Velho, Rochelle
    Uppal, Hardeep
    Heun, Reinhard
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2011, 18 (12) : 1746 - 1747
  • [5] Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease
    van de Vijver, DAMC
    Stricker, BHC
    Breteler, MMB
    Roos, RAC
    Porsius, AJ
    de Boer, A
    [J]. PHARMACY WORLD & SCIENCE, 2001, 23 (04): : 148 - 152
  • [6] Treatment in Parkinson's disease - Pharmacoepidemiological research into the consumption of Antiparkinsonian drugs
    Brefel-Courbon, C.
    Grolleau, S.
    Bourrel, R.
    Allaria-Lapierre, V.
    Loi, R.
    Micallef-Roll, J.
    Lapeyre-Mestre, M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 49 - 49
  • [7] Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease
    D.A.M.C. van de Vijver
    A.J. Porsius
    A. de Boer
    B.H.Ch. Stricker
    M.M.B. Breteler
    R.A.C. Roos MD
    J. Hewison
    [J]. Pharmacy World and Science, 2001, 23 : 148 - 152
  • [8] AntiParkinsonian treatment patterns and motor complications among patients with Parkinson's disease in Estonia
    Kadastik-Eerme, L.
    Taba, N.
    Taba, P.
    [J]. MOVEMENT DISORDERS, 2016, 31 : S622 - S622
  • [9] ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs
    Vautier, Sarah
    Fernandez, Christine
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (11) : 1349 - 1358
  • [10] Tracking Parkinson's: A United Kingdom cohort study in Parkinson's disease
    Malek, N.
    Grosset, K. A.
    Lawton, M. A.
    Bajaj, N.
    Barker, R. A.
    Ben-Shlomo, Y.
    Burn, D. J.
    Foltynie, T.
    Morris, H. R.
    Williams, N. M.
    Wood, N. W.
    Grosset, D. G.
    [J]. MOVEMENT DISORDERS, 2015, 30 : S407 - S407
12345